Life Sciences AISeedWorkflowℹ115 viewsOutput Labs
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations.
Company snapshot
- Stage
- Seed
- Funding
- Seed (YC S21)
- Status
- published
- Updated
- Nov 4, 2026
- Views
- 115 views
- Category
- Life Sciences AI
- Website
- outputlabs.ai
What they're building
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations. Output Labs develops AI systems for mechanistic reasoning, aiming to model how complex systems work and apply those explanations to scientific problems.
Founders
Adi Mashiach, MD
Co-founder
Mirella Mashiach
Co-founder
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Agentic loops, Batch document processing, Multimodal processing
- Estimated model demand
- High intensity
NYC footprint
- NYC presence
- NYC company or team supported by public sources. Street address has not been verified.
Funding
Latest funding: Seed (YC S21). Lead investor: Y Combinator.
AI Lab Fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Current AI product, canonical identity, active operations and NYC presence. Funding not rechecked unless a linked funding correction is recorded. Preserve one company identity. Apply canonical URL/name/copy corrections to the existing record; do not add a second card for the corrected identity. Publication is conditional on repairs.
Notes
Output Labs is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹ161viewsRecent Activity
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.
Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.
Life Sciences AIInfraℹRecent Activity
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Life Sciences AIWorkflowℹRecent Activity